Abstract
This review article focuses on the past and future aspects of vascular endothelial growth factor inhibitors in Cervical Cancer.Vascular endothelial growth factor (VEGF)-mediated angiogenesis is considered to play a vital function in the tumor development and metastasis. Therefore, VEGF-inhibitors are being actively considered as prospective anticancer treatment. The most widely studied tyrosine kinase inhibitors that target VEGF or anti- VEGF monoclonal antibodies and receptors, promise significant results in clinical trials.
Key words: Vascular Endothelial Growth Factor; Tyrosine Kinase Inhibitor; Angiogenesis; Human Papilloma Virus; Anti-Angiogenesis Factor.
Download Pdf